Tags

Type your tag names separated by a space and hit enter

Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Eur J Cancer. 2011 Aug; 47(12):1779-88.EJ

Abstract

BACKGROUND

The aim of this study was to investigate whether c-myc amplification in human breast cancer is associated with response to neoadjuvant chemotherapy comprising paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC).

METHODS

Tumour tissue samples were obtained before neoadjuvant chemotherapy (P-FEC) from 100 primary breast cancer patients (stage II/III). C-myc and HER2 amplification were examined by FISH, and oestrogen receptor (ER), progesterone receptor (PR), Ki67, and topoisomerase 2α (TOP2A) expression were examined immunohistochemically. Pathological complete response (pCR) was defined by a complete loss of tumour cells in the breast without any lymph node metastasis.

RESULTS

C-myc amplification was observed in 40% (40/100) of breast tumours, and was significantly associated with ER-negative tumours (23/40 for ER(-) versus 17/60 for ER(+), P=0.004), high histological grade tumours (11/18 for grade 3 versus 29/82 for grades 1+2, P=0.043) and TOP2A-positive tumours (28/51 for TOP2A(+) versus 12/49 for TOP2A(-), P=0.002). pCR rate was 20% for total patients (10.0% for ER(+) and 35.0% for ER(-)). Further, breast tumours with c-myc amplification (c-myc(+)) showed a significantly (P=0.041) higher pCR rate (12/40) than those without such amplification (c-myc(-)) (8/60). This association between pCR and c-myc amplification was observed in ER-positive tumours (4/17 for c-myc(+) versus 2/43 for c-myc(-), P=0.048) but not in ER-negative tumours (8/23 for c-myc(+) versus 6/17 for c-myc(-), P=0.973).

CONCLUSION

Our results suggest that c-myc amplification is significantly associated with a high pCR rate to P-FEC in breast tumours, especially in ER-positive tumours.

Authors+Show Affiliations

Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21741827

Citation

Yasojima, Hiroyuki, et al. "Association Between C-myc Amplification and Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer." European Journal of Cancer (Oxford, England : 1990), vol. 47, no. 12, 2011, pp. 1779-88.
Yasojima H, Shimomura A, Naoi Y, et al. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Eur J Cancer. 2011;47(12):1779-88.
Yasojima, H., Shimomura, A., Naoi, Y., Kishi, K., Baba, Y., Shimazu, K., Nakayama, T., Kim, S. J., Tamaki, Y., & Noguchi, S. (2011). Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. European Journal of Cancer (Oxford, England : 1990), 47(12), 1779-88. https://doi.org/10.1016/j.ejca.2011.06.017
Yasojima H, et al. Association Between C-myc Amplification and Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Eur J Cancer. 2011;47(12):1779-88. PubMed PMID: 21741827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. AU - Yasojima,Hiroyuki, AU - Shimomura,Atsushi, AU - Naoi,Yasuto, AU - Kishi,Kazuki, AU - Baba,Yousuke, AU - Shimazu,Kenzo, AU - Nakayama,Takahiro, AU - Kim,Seung Jin, AU - Tamaki,Yasuhiro, AU - Noguchi,Shinzaburo, Y1 - 2011/07/07/ PY - 2011/01/17/received PY - 2011/06/07/revised PY - 2011/06/07/accepted PY - 2011/7/12/entrez PY - 2011/7/12/pubmed PY - 2011/10/4/medline SP - 1779 EP - 88 JF - European journal of cancer (Oxford, England : 1990) JO - Eur J Cancer VL - 47 IS - 12 N2 - BACKGROUND: The aim of this study was to investigate whether c-myc amplification in human breast cancer is associated with response to neoadjuvant chemotherapy comprising paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC). METHODS: Tumour tissue samples were obtained before neoadjuvant chemotherapy (P-FEC) from 100 primary breast cancer patients (stage II/III). C-myc and HER2 amplification were examined by FISH, and oestrogen receptor (ER), progesterone receptor (PR), Ki67, and topoisomerase 2α (TOP2A) expression were examined immunohistochemically. Pathological complete response (pCR) was defined by a complete loss of tumour cells in the breast without any lymph node metastasis. RESULTS: C-myc amplification was observed in 40% (40/100) of breast tumours, and was significantly associated with ER-negative tumours (23/40 for ER(-) versus 17/60 for ER(+), P=0.004), high histological grade tumours (11/18 for grade 3 versus 29/82 for grades 1+2, P=0.043) and TOP2A-positive tumours (28/51 for TOP2A(+) versus 12/49 for TOP2A(-), P=0.002). pCR rate was 20% for total patients (10.0% for ER(+) and 35.0% for ER(-)). Further, breast tumours with c-myc amplification (c-myc(+)) showed a significantly (P=0.041) higher pCR rate (12/40) than those without such amplification (c-myc(-)) (8/60). This association between pCR and c-myc amplification was observed in ER-positive tumours (4/17 for c-myc(+) versus 2/43 for c-myc(-), P=0.048) but not in ER-negative tumours (8/23 for c-myc(+) versus 6/17 for c-myc(-), P=0.973). CONCLUSION: Our results suggest that c-myc amplification is significantly associated with a high pCR rate to P-FEC in breast tumours, especially in ER-positive tumours. SN - 1879-0852 UR - https://www.unboundmedicine.com/medline/citation/21741827/Association_between_c_myc_amplification_and_pathological_complete_response_to_neoadjuvant_chemotherapy_in_breast_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(11)00421-7 DB - PRIME DP - Unbound Medicine ER -